Impact of postpartum tenofovir-based antiretroviral therapy on bone mineral density in breastfeeding women with HIV enrolled in a randomized clinical trial
Open Access
- 5 February 2021
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 16 (2), e0246272
- https://doi.org/10.1371/journal.pone.0246272
Abstract
Objectives: We set out to evaluate the effect of postnatal exposure to tenofovir-containing antiretroviral therapy on bone mineral density among breastfeeding women living with HIV. Design: IMPAACT P1084s is a sub-study of the PROMISE randomized trial conducted in four African countries (ClinicalTrials.gov number NCT01066858). Methods: IMPAACT P1084s enrolled eligible mother-infant pairs previously randomised in the PROMISE trial at one week after delivery to receive either maternal antiretroviral therapy (Tenofovir disoproxil fumarate / Emtricitabine + Lopinavir/ritonavir–maternal TDF-ART) or administer infant nevirapine, with no maternal antiretroviral therapy, to prevent breastmilk HIV transmission. Maternal lumbar spine and hip bone mineral density were measured using dual-energy x-ray absorptiometry (DXA) at postpartum weeks 1 and 74. We studied the effect of the postpartum randomization on percent change in maternal bone mineral density in an intention-to-treat analysis with a t-test; mean and 95% confidence interval (95%CI) are presented. Results: Among 398/400 women included in this analysis, baseline age, body-mass index, CD4 count, mean bone mineral density and alcohol use were comparable between study arms. On average, maternal lumbar spine bone mineral density declined significantly through week 74 in the maternal TDF-ART compared to the infant nevirapine arm; mean difference (95%CI) -2.86 (-4.03, -1.70) percentage points (p-value <0.001). Similarly, maternal hip bone mineral density declined significantly more through week 74 in the maternal TDF-ART compared to the infant nevirapine arm; mean difference -2.29% (-3.20, -1.39) (p-value <0.001). Adjusting for covariates did not change the treatment effect. Conclusions: Bone mineral density decline through week 74 postpartum was greater among breastfeeding HIV-infected women randomized to receive maternal TDF-ART during breastfeeding compared to those mothers whose infants received nevirapine prophylaxis.Funding Information
- National Institute of Allergy and Infectious Diseases (UM1AI068632)
- National Institute of Allergy and Infectious Diseases (UM1AI068616)
- National Institute of Allergy and Infectious Diseases (UM1AI106716)
- Eunice Kennedy Shriver National Institute of Child Health and Human Development
- National Institute of Mental Health
This publication has 45 references indexed in Scilit:
- Changes in bone mineral density over a 2-year period in HIV-1-infected men under combined antiretroviral therapy with osteopeniaAIDS, 2013
- Factors determining bone mineral density loss in chronic hepatitis B patients: is tenofovir disoproxil fumarate the main culprit?Gut, 2011
- Loss of Bone Mineral Density After Antiretroviral Therapy Initiation, Independent of Antiretroviral RegimenJAIDS Journal of Acquired Immune Deficiency Syndromes, 2009
- Decreased Bone Mineral Density with Off-Label Use of Tenofovir in Children and Adolescents Infected with Human Immunodeficiency VirusThe Journal of Pediatrics, 2008
- Evolution of bone mineral density in AIDS patients on treatment with zidovudine/lamivudine plus abacavir or lopinavir/ritonavirHIV Medicine, 2007
- Emerging Bone Problems in Patients Infected with Human Immunodeficiency VirusClinical Infectious Diseases, 2003
- Longitudinal Evolution of Bone Mineral Density and Bone Markers in Human Immunodeficiency Virus–Infected IndividualsClinical Infectious Diseases, 2003
- Bone Mineral Changes During Pregnancy and LactationEndocrine, 2002
- Bone mineral changes during and after lactationObstetrics & Gynecology, 1999
- Bone mineral loss during lactation and recovery after weaningObstetrics & Gynecology, 1995